Reportedly, a booster dose of Johnson & Johnson (JNJ) Inc’s single-dose COVID-19 vaccine has proven to be 84% effective at preventing hospitalization in South African healthcare workers who became infected with the fast-spreading Omicron variant. The real-world study was based on a second dose of the J&J vaccine administered to 69,092 healthcare workers between Nov. 15 and Dec. 20.
The South African study of the J&J shot showed that the vaccine’s effectiveness at preventing hospitalization increased from 63% shortly after a booster was administered to 84% 14 days later, the effectiveness reached 85% at one to two months post the booster shot. Scientists in South Africa first alerted the World Health Organization about Omicron in late November, a highly infectious variant that is spreading quickly in other countries.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.